• The Roche Annual General Meeting 2020 will be held under conditions of the COVID-19 Ordinance 2 of the Federal Council
• To comply with regulatory requirements, voting at the AGM will be by independent proxy
• Shareholders who are physically present will be able to cast their votes through the proxy, but will not be admitted to the meeting rooms
  
  

Basel, 16 March 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that due to the declaration of the extraordinary situation by the Federal Council to combat the corona virus, voting at tomorrow's Ordinary General Meeting will be done by the independent proxies. Roche is thus complying with Ordinance 2 on Measures to Combat the Corona Virus (COVID-19) (COVID-19- 2) as amended on 16 March.

Shareholders on site cannot be granted access to the meeting room. They may submit their votes to the independent proxy on site. Urgent questions can be submitted in writing to Investor Relations at https://www.roche.com/de/investors.htm.

Roche again requests that shareholders refrain from travel and stay away from the meeting.

Further information can be found at
https://www.roche.com/about/governance/annual_general_meetings.htm.

About Roche
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the eleventh consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2019 employed about 98,000 people worldwide. In 2019, Roche invested CHF 11.7 billion in R&D and posted sales of CHF 61.5 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.


Roche Group Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com
- Nicolas Dunant (Head)
- Patrick Barth
- Daniel Grotzky
- Karsten Kleine
- Nathalie Meetz
- Barbara von Schnurbein

Attachment

• 16032020_Roche AGM statement_EN